Optimal blood pressure: how low should we go?

作者: H BLACK

DOI: 10.1016/S0895-7061(99)00207-1

关键词:

摘要: The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure defines hypertension as systolic blood pressure > or =140 mm Hg diastolic (DBP) =90 Hg. Evidence shows that even slightly elevated significantly increases the risk morbidity mortality only aggressive efforts to reduce can this risk. In recently completed Hypertension Optimal trial, patients were assigned one three target groups, reflecting DBP goals < =90, =85, =80 Aggressive antihypertensive treatment allowed more than 90% achieve goal This study clearly showed these defined could be safely met exceeded. Too few with receive level effective achieved in clinical trials. Individuals poorly controlled are at significant for cardiovascular cerebrovascular represent a potentially substantial burden healthcare system. Setting appropriate working meet them through treatment, multiple agents if necessary, those risks.

参考文章(25)
A. Rodgers, S. MacMahon, G. Gamble, J. Slattery, P. Sandercock, C. Warlow, Blood pressure and risk of stroke in patients with cerebrovascular disease BMJ. ,vol. 313, pp. 147- 147 ,(1996) , 10.1136/BMJ.313.7050.147
Michael A. Moore, Murray Epstein, Lawrence Agodoa, Lance D. Dworkin, Current Strategies for Management of Hypertensive Renal Disease Archives of Internal Medicine. ,vol. 159, pp. 23- 28 ,(1999) , 10.1001/ARCHINTE.159.1.23
JohnM. Cruickshank, JeffreyM. Thorp, F.James Zacharias, BENEFITS AND POTENTIAL HARM OF LOWERING HIGH BLOOD PRESSURE The Lancet. ,vol. 329, pp. 581- 584 ,(1987) , 10.1016/S0140-6736(87)90231-5
Henry R Black, William J Elliott, James D Neaton, Gregory Grandits, Patricia Grambsch, Richard H Grimm Jr, Lennart Hansson, Yves Lacoucière, James Muller, Peter Sleight, Michael A Weber, William B White, Gordon Williams, Janet Wittes, Alberto Zanchetti, T Daniel Fakouhi, None, Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial Controlled Clinical Trials. ,vol. 19, pp. 370- 390 ,(1998) , 10.1016/S0197-2456(98)00013-0
Christopher G. Isles, Louise M. Walker, Gareth D. Beevers, Irene Brown, Helen L. Cameron, John Clarke, Victor Hawthorne, David Hole, Anthony F. Lever, James W.K. Robertson, Jean A. Wapshaw, Mortality in patients of the Glasgow Blood Pressure Clinic. Journal of Hypertension. ,vol. 4, pp. 141- 156 ,(1986) , 10.1097/00004872-198604000-00003
P Marques-Vidal, J Tuomilehto, Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? Journal of Human Hypertension. ,vol. 11, pp. 213- 220 ,(1997) , 10.1038/SJ.JHH.1000426
TerenceW. Anderson, Re-examination of some of the Framingham blood-pressure data. The Lancet. ,vol. 312, pp. 1139- 1141 ,(1978) , 10.1016/S0140-6736(78)92288-2
Nanette K. Wenger, Margaret E. Mattson, Jack Elinson, Curt D. Furberg, Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies ,(1984)
Michael H Alderman, Wee L Ooi, Shantha Madhavan, Hillel Cohen, Treatment-Induced Blood Pressure Reduction and the Risk of Myocardial Infarction JAMA: The Journal of the American Medical Association. ,vol. 262, pp. 920- 924 ,(1989) , 10.1001/JAMA.1989.03430070068032